OTC · ONVVF
Oneview Healthcare PLC
$0.15$0.00 (0.0%)
Oneview Healthcare PLC’s quoted price sits in the lower half of its reported 52-week range, 6.25% below the high.
Loading market information…
ASX · TRJ.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 03:01 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Trajan Group Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 68.55% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Trajan Group Holdings Limited’s next earnings report is currently expected on Mar 1, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Trajan Group Holdings Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Headquartered in Ringwood, Australia, and established in 2011, Trajan Group Holdings Limited is a global enterprise focused on designing, manufacturing, marketing, and distributing a diverse range of analytical and life science instruments and associated products. Its extensive operations cover Australia, New Zealand, Malaysia, Japan, the United States, Europe, the Middle East, Africa, and India. The company's activities are organized into two main divisions: Analytical Products and Life Science Solutions. The Analytical Products segment provides essential components such as syringes, GC consumables, septa, caps, liners, gas filters, and tubing. It also supplies pathology and sampling equipment, along with automated systems tailored for examining biological, food, and environmental samples. Complementing this, Trajan delivers nutrition testing solutions for various clients, including pathology laboratories, research and clinical trial initiatives, personalized nutrition programs, corporate wellness strategies, and health insurance providers. The company's offerings further extend to automation workflow solutions, micro-sampling devices, and comprehensive data analysis services.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:50 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Aug 28, 2023 |
| -A$0.01 |
| A$82.10M-46.66% vs estimate |
| Q2 2023 | Feb 26, 2023 | A$0.00 | A$80.06M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.15$0.00 (0.0%)
Oneview Healthcare PLC’s quoted price sits in the lower half of its reported 52-week range, 6.25% below the high.
A$1.40+A$0.00 (+0.14%)
SDI Limited’s quoted price sits in the upper half of its reported 52-week range, 0.21% below the high.
A$0.04-A$0.00 (-2.33%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
A$0.11-A$0.01 (-4.35%)
Alcidion Group Limited’s quoted price sits in the lower half of its reported 52-week range, 24.14% below the high.
A$2.74A$0.00 (0.0%)
Vita Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 5.52% below the high.
A$0.36+A$0.03 (+9.09%)
Recce Pharmaceuticals Ltd’s quoted price sits in the lower half of its reported 52-week range, 50.68% below the high.
A$0.28A$0.00 (0.0%)
Austco Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 37.08% below the high.
A$0.29-A$0.04 (-10.77%)
Island Pharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 53.97% below the high.
